Meda AB buys Elidel from Novartis for $420mm
Executive Summary
Novartis AG has sold specialty pharma Meda AB global marketing and manufacturing rights to Elidel (pimecrolimus) cream 1% for mild-to-moderate atopic dermatitis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice